In the US cohort study published in JAMA Dermatology 2025, the risk of non-melanocytic skin cancer (NMSC) was reduced in patients who had received nicotinamide supplementation – especially if the supplementation took place after a first NMSC disease. The risk reduction was significantly higher for squamous cell carcinomas than for basal cell carcinomas.
Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich
Jetzt beitreten
Jetzt beitreten
Already a member? Log in here
